Survival Prognosis, Tumor Immune Landscape, and Immune Responses of PPP1R18 in Kidney Renal Clear Cell Carcinoma and Its Potentially Double Mechanisms
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Background: The aim of this study was to investigate the immunological and prognostic roles of protein phosphatase 1 regulatory subunit 18 (PPP1R18) for overall survival (OS) in kidney renal clear cell carcinoma (KIRC) patients, as well as the prediction of its potential mechanisms. Methods: Based on PPP1R18 single gene expression matrices and clinical information from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC) and GSE6344 datasets, the relationships between PPP1R18 and prognosis/immunity were fully explored. Univariate and multivariate Cox regression analyses were applied to assess its independent prognostic ability and gene set enrichment analysis (GSEA) was implemented to find its related pathways. Besides, we also explored possible mechanisms of PPP1R18 involved in KIRC. Results: PPP1R18 was highly expressed in KIRC samples than in non-tumor tissues in TCGA, ICGC and GSE6344 datasets, with validations from quantitative real-time polymerase chain reaction (qRT-PCR) in both cell lines and KIRC tissues (all P < 0.05). Univariate and multivariate Cox regression analyses indicated that PPP1R18 was also considered to be with independent prognostic ability in KIRC (both P < 0.01). GSEA results showed that PPP1R18 gene expression was significantly related to Chemokine, JAK STAT, MAPK, and NOTCH pathways. Furthermore, PPP1R18 was also firmly associated with microsatellite instability (MSI), tumor mutational burden (TMB), immune microenvironment, immune cells, immune checkpoints and immune infiltration (all P < 0.05). Analysis of tumor immune dysfunction and exclusion (TIDE) and Imvigor210 datasets suggested that patients with low PPP1R18 expression are more likely to benefit from immunotherapy. Finally, we identified two potential mechanisms of a classical competing endogenous RNA (ceRNA) mechanism and an RNA-binding protein (RBP) involved mechanism of PPP1R18 in KIRC. Conclusions: PPP1R18 played oncogenic and immunological roles of OS in KIRC, offering potential antigens for developing KIRC mRNA vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“suggest that PPP1R18 likely functions as an oncogene associated with poor prognosis in ccRCC”
From PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma (2026) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0136-1 · Cited by 5,179
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · cited 1×
“Based on previously published studies [11] and the Simple Nucleotide Variation dataset of level 4 for all TCGA samples processed by MuTect2 software [12], microsatellite instability (MSI) scores and tumor mutational burden (TMB) scores for each tumor were obtained [13], integrating with gene expression data.”
MethodEAU Guidelines on Renal Cell Carcinoma: 2014 Update
Ljungberg, B., Bensalah, K., Canfield, S., Dabestani, S., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T., Marconi, L., Merseburger, A. S., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.005 · Cited by 3,394 · cited 1×
“Less than 15% of patients will present with the classic symptoms of abdominal pain, hematuria, and a mass [25-27].”
BackgroundHoller, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J.-L., Schneider, P., Seed, B., & Tschopp, J. (2000) · Nature Immunology · doi:10.1038/82732 · Cited by 1,938 · cited 1×
“The mortality rate of patients with KIRC has remained high due to lack of sensitivity to radiotherapy, and we have explored many areas such as molecularly targeted therapies [28, 29].”
BackgroundLandscape of Microsatellite Instability Across 39 Cancer Types
Bonneville, R., Krook, M. A., Kautto, E. A., Miya, J., Wing, M. R., Chen, H.-Z., Reeser, J. W., Yu, L., & Roychowdhury, S. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00073 · Cited by 1,476 · cited 1×
“Based on previously published studies [11] and the Simple Nucleotide Variation dataset of level 4 for all TCGA samples processed by MuTect2 software [12], microsatellite instability (MSI) scores and tumor mutational burden (TMB) scores for each tumor were obtained [13], integrating with gene expression data.”
MethodClear cell renal cell carcinoma ontogeny and mechanisms of lethality
Jonasch, E., Walker, C. L., & Rathmell, W. K. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00359-2 · Cited by 644 · cited 1×
“Less than 15% of patients will present with the classic symptoms of abdominal pain, hematuria, and a mass [25-27].”
BackgroundYamaguchi, H., Hsu, J.-M., Yang, W.-H., & Hung, M.-C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 493 · cited 1×
“They can block the binding of PD1 and PDL1, increasing the proliferation of T cells, then it could enhance the recognition ability and killing function of T cells on tumor cells, and achieve anti-tumor effects [34, 35].”
BackgroundLuciani, L. G., Cestari, R., & Tallarigo, C. (2000) · Urology · doi:10.1016/s0090-4295(00)00534-3 · Cited by 452
Pyroptosis, metabolism, and tumor immune microenvironment
Du, T., Gao, J., Li, P., Wang, Y., Qi, Q., Liu, X., Li, J., Wang, C., & Du, L. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.492 · Cited by 324 · cited 1×
“And there are some links between these genes and the immune microenvironment [32, 33].”
BackgroundSelf-citationGene set enrichment analysis: performance evaluation and usage guidelines
Hung, J.-H., Yang, T.-H., Hu, Z., Weng, Z., & DeLisi, C. (2012) · Briefings in Bioinformatics · doi:10.1093/bib/bbr049 · Cited by 266 · cited 1×
“As described in previously published studies [17-19], PPP1R18-related pathways in this study were also investigated by applying GSEA.”
ResultChallenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
Upadhaya, S., Neftelinov, S. T., Hodge, J., & Campbell, J. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00030-4 · Cited by 210
Yu, Y.-Z., Lv, D.-J., Wang, C., Song, X.-L., Xie, T., Wang, T., Li, Z.-M., Guo, J.-D., Fu, D.-J., Li, K.-J., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01480-x · Cited by 187 · cited 2×
“Moreover, inspired by the recent article (DOI: https://doi.org/10.1186/ s12943-021-01480-x) published in Molecular Cancer, Yu et al revealed the double mechanisms of hsa_circ_0003258 in prostate cancer (PCa) progression by a classical competing endogenous RNA (ceRNA) mechanism (hsa_circ_0003258/IGF2BP3/ HDAC4 axis) an…”
BackgroundInfluentialColon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment
Jahanafrooz, Z., Mosafer, J., Akbari, M., Hashemzaei, M., Mokhtarzadeh, A., & Baradaran, B. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29337 · Cited by 165 · cited 1×
“In the era of cancer precision medicine, cancer personalized therapy today could be much easier to be facilitated with the knowledge of cancer-specific genomics [3, 4].”
BackgroundThe molecular feature of macrophages in tumor immune microenvironment of glioma patients
Zhang, H., Luo, Y., Wu, W., Zhang, L., Wang, Z., Dai, Z., Feng, S., Cao, H., Cheng, Q., & Liu, Z. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.019 · Cited by 165 · cited 1×
“And there are some links between these genes and the immune microenvironment [32, 33].”
BackgroundInamura, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102195 · Cited by 162 · cited 1×
“Less than 15% of patients will present with the classic symptoms of abdominal pain, hematuria, and a mass [25-27].”
BackgroundZhang, S., Zhu, L., Peng, Y., Zhang, L., Chao, F., Jiang, L. H., Xiao, Q., Liang, X., Tang, J., Yang, H., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02401-5 · Cited by 155 · cited 1×
“As described in previously published studies [17-19], PPP1R18-related pathways in this study were also investigated by applying GSEA.”
ResultWang, W., Hu, W., Wang, Y., An, Y., Song, L., Shang, P., & Yue, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1132-x · Cited by 123 · cited 1×
“As for the potential mechanisms of PPP1R18 involved in KIRC, we referred to previous published articles [22-24] and design two approaches to identify two potential mechanisms of a classical ceRNA mechanism (LncRNA/miRNA/ PPP1R18 mRNA networks) and an RBP involved mechanism (LncRNA/RBP/PPP1R18 mRNA networks) with the h…”
MethodSelf-citationWang, A.-B., Bao, Y., Wu, Z.-J., Zhao, T.-L., Wang, D., Shi, J.-Z., Liu, B., Sun, S.-H., Yang, F., Wang, L.-H., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1331-9 · Cited by 117 · cited 2×
“As for the potential mechanisms of PPP1R18 involved in KIRC, we referred to previous published articles [22-24] and design two approaches to identify two potential mechanisms of a classical ceRNA mechanism (LncRNA/miRNA/ PPP1R18 mRNA networks) and an RBP involved mechanism (LncRNA/RBP/PPP1R18 mRNA networks) with the h…”
BackgroundMethodConcomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
Hopkins, A. M., Kichenadasse, G., Karapetis, C. S., Rowland, A., & Sorich, M. J. (2020) · European Urology · doi:10.1016/j.eururo.2020.06.061 · Cited by 107 · cited 1×
“Imvigor210 data were also downloaded for predicting immunotherapy response [21].”
MethodZou, Z., Ma, T., He, X., Zhou, J., Ma, H., Xie, M., Liu, Y., Lü, D., Di, S., & Zhang, Z. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0758-8 · Cited by 106 · cited 1×
“The study by Zou et al showed that LINC00324 promotes gastric cancer cell proliferation with the help of binding to HuR and stabilizing FAM83B expression [39].”
BackgroundZhu, Z., Cao, C., Zhang, D., Zhang, Z., Liu, L., Wu, D., & Sun, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04596-0 · Cited by 66 · cited 1×
“As described in previously published studies [17-19], PPP1R18-related pathways in this study were also investigated by applying GSEA.”
ResultHa, Y. J., Tak, K. H., Kim, C. W., Roh, S. A., Choi, E. K., Cho, D. H., Kim, J., Kim, S., Kim, S., Kim, Y. S., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.03.023 · Cited by 45 · cited 2×
“As for cancer research, Ha et al identified eight differentially expressed genes above 16-fold changes including PPP1R18, that were significantly related to preoperative chemoradiation therapy responses in rectal cancer [8].”
BackgroundPeng, D., Wei, C., Zhang, X., Li, S., Liang, H., Zheng, X., Jiang, S., & Han, L. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02266-3 · Cited by 39
Lv, Q., Dong, F., Zhou, Y., Cai, Z., & Wang, G. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03268-1 · Cited by 36 · cited 1×
“A study revealed RBP SORBS2 inhibits KIRC transfer by enhancing MTUS1 mRNA stability [38].”
BackgroundQi, Y., Ma, Y., Peng, Z., Wang, L., Li, L., Tang, Y., He, J., & Zheng, J. (2020) · Oncogene · doi:10.1038/s41388-020-1297-1 · Cited by 36 · cited 1×
“Another lncPENG/miR-15b/PDZK1 mRNA network identified by Qi et al is involved in the regulation of tumor cell proliferation, in which LncPENG acts as a ceRNA to attenuate miR-15bdependent PDZK1 down-regulation and inhibit cell proliferation [37].”
BackgroundSu, Y. A., Yang, J. H., Tao, L., Nguyen, H. T., & He, P. (2010) · Journal of Cancer · doi:10.7150/jca.1.38 · Cited by 31 · cited 1×
“In addition, expression levels of PPP1R18 were also reported to be decreased in breast cancer cells, suggesting an anticancer effect [10].”
BackgroundPersonalized Therapy for Breast Cancer: A Dream or a Reality?
Zardavas, D., Pugliano, L., & Piccart, M. J. (2013) · Future Oncology · doi:10.2217/fon.13.57 · Cited by 31 · cited 1×
“In the era of cancer precision medicine, cancer personalized therapy today could be much easier to be facilitated with the knowledge of cancer-specific genomics [3, 4].”
BackgroundBiomarker-Oriented Therapy in Bladder and Renal Cancer
Scholtes, M., Alberts, A. R., Iflé, I. G., Verhagen, P. C. M. S., van der Veldt, A. A. M., & Zuiverloon, T. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062832 · Cited by 29 · cited 1×
“The mortality rate of patients with KIRC has remained high due to lack of sensitivity to radiotherapy, and we have explored many areas such as molecularly targeted therapies [28, 29].”
BackgroundPrevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
Attalla, K., DiNatale, R. G., Rappold, P. M., Fong, C. J., Sánchez-Vega, F., Silagy, A. W., Weng, S., Coleman, J., Lee, C., Carlo, M. I., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4058 · Cited by 29
Matsubara, T., Kokabu, S., Nakatomi, C., Kinbara, M., Maeda, T., Yoshizawa, M., Yasuda, H., Takano-Yamamoto, T., Baron, R., & Jimi, E. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00425-17 · Cited by 28 · cited 2×
“To our knowledge, PPP1R18, also known as HKMT1098, KIAA1949, was reported to be a protein phosphatase 1 (PP1)-binding protein, or an actin-regulatory protein [6, 7].”
BackgroundCircAGAP1 promotes tumor progression by sponging miR-15-5p in clear cell renal cell carcinoma
Lv, Q., Wang, G., Zhang, Y., Shen, A., Tang, J., Sun, Y., Ma, C., & Wang, P. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01864-3 · Cited by 26 · cited 1×
“network was shown to be involved in tumor progression [36].”
BackgroundTian, Z., Yuan, C., Yang, K., & Gao, X.-L. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.18 · Cited by 24 · cited 1×
“related to KIRC by some bioinformatics analyses [30] and is associated with poor prognosis in immunophenotyping subtype C1 [31].”
BackgroundPan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy
Liu, J., Wang, Y., Yin, J., Yang, Y. T., Geng, R., Zhong, Z., Ni, S., Liu, W., Du, M., Yu, H., et al. (2022) · Journal of Oncology · doi:10.1155/2022/3477148 · Cited by 24
Self-citationWang, Y., Tian, Y., Liu, S., Wang, Z., & Xing, Q. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02322-y · Cited by 18 · cited 1×
“As for the potential mechanisms of PPP1R18 involved in KIRC, we referred to previous published articles [22-24] and design two approaches to identify two potential mechanisms of a classical ceRNA mechanism (LncRNA/miRNA/ PPP1R18 mRNA networks) and an RBP involved mechanism (LncRNA/RBP/PPP1R18 mRNA networks) with the h…”
MethodSelf-citationMulti-Omics Analysis of the Effects of Smoking on Human Tumors
Wang, R., Li, S., Wen, W., & Zhang, J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.704910 · Cited by 17 · cited 2×
“Wang et al revealed that PPP1R18 was found to be a possible methylation driver gene associated with smoking-induced tumors on cancer patients with different smoking histories [9].”
BackgroundBai, D., Chen, S., Feng, H., Yin, A., Lu, J., Ma, Y., & Sugiyama, H. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153557 · Cited by 16 · cited 1×
“related to KIRC by some bioinformatics analyses [30] and is associated with poor prognosis in immunophenotyping subtype C1 [31].”
BackgroundYasuda, K., Matsubara, T., Shirakawa, T., Kawamoto, T., & Kokabu, S. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101114 · Cited by 15 · cited 2×
“To our knowledge, PPP1R18, also known as HKMT1098, KIAA1949, was reported to be a protein phosphatase 1 (PP1)-binding protein, or an actin-regulatory protein [6, 7].”
BackgroundMa, L., Jin, G., Yao, K., Yang, Y., Chang, R., Wang, W., Liu, J., & Zhu, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.699892 · Cited by 11
Prevalence and landscape of actionable genomic alterations in renal cell carcinoma.
Attalla, K., DiNatale, R. G., Reznik, E., Fong, C. J., Sánchez-Vega, F., Silagy, A. W., Weng, S., Coleman, J., Lee, C., Carlo, M. I., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.6_suppl.616 · Cited by 3 · cited 1×
“Based on previously published studies [11] and the Simple Nucleotide Variation dataset of level 4 for all TCGA samples processed by MuTect2 software [12], microsatellite instability (MSI) scores and tumor mutational burden (TMB) scores for each tumor were obtained [13], integrating with gene expression data.”
Method
Cited by
Su, Y., Zhang, T., Lu, J., Qian, L., Fei, Y., Zhang, L., Fan, S., Zhou, J., Tang, J., Chen, H., et al. (2023) · Cells · doi:10.3390/cells12010180 · Cited by 20
“PPP1R18 is highly expressed in ccRCC cell lines and tissues [50].”
BackgroundLiu, S., Yu, Y. W., Wang, Y., Zhu, B., & Han, B. (2022) · European journal of medical research · doi:10.1186/s40001-022-00745-5 · Cited by 13
“As the same manner described in our previous article [12], we finally mined COLGALT1 as a potential biomarker in TCGA–KIRC data set, after a series of gene filtration methods.”
MethodSelf-citationZhang, X., Ji, H., Huang, Y., Zhu, B., & Xing, Q. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13201 · Cited by 9
Self-citationCorrelation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma
Li, L., & Li, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1128785 · Cited by 9
“Frontiers in Oncology 08 Wang W (48) and Qi YA et al.”
BackgroundChen, Q., Xing, C. M., Zhang, Q., Du, Z., Kong, J., & Qian, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-64627-y · Cited by 6
“This study was approved by the Institutional Research Ethics Committees of Affiliated Hospital of Nantong University.”
Method
Metadata
- Authors
- Wang, Y., Liu, S., Chen, Y., Zhu, B., & Xing, Q.
- Affiliations
- Affiliated Hospital of Nantong University (CN)
- Jiangsu Province Hospital (CN)
- Corresponding author
- Zhu, Bingye
- Xing, Qianwei
- Venue
- World Journal of Oncology
- Publisher
- Elmer Press, Inc.
- Published
- 2022-02
- Volume
- 13
- Issue
- 1
- Pages
- 27-37
- ISSN
- 1920-4531 (ISSN-L)
- 1920-454X
- PMC
- PMC8913016
- OpenAlex
- W4214537915
- Cited by
- 17
- References
- 41
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 3
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- World Journal of Oncology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- clear cell renal cell carcinoma, prognostic factors, tumor immune microenvironment, immune checkpoint, tumor immune dysfunction and exclusion, immunotherapy response, competing endogenous RNA, RNA-binding proteins, chemokine pathways, JAK/STAT signaling, MAPK signaling, Notch signaling, microsatellite instability, tumor mutational burden, mRNA vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.